PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: Immuno-PET and TKI-PET

Tumor Biology

Volumn 33, Issue 3, 2012, Pages 607-615

  Van Dongen, Guus A M S ^a   Poot, Alex J ^a   Vugts, Danielle J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Carbon 11; Fluorine 18; Monoclonal antibodies; Positron emission tomography; Tyrosine kinase inhibitors; Zirconium 89

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CETUXIMAB; DASATINIB; ERLOTINIB; ERLOTINIB C 11; GEFITINIB; GEFITINIB C 11; GEFITINIB F 18; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMATINIB; IPILIMUMAB; LAPATINIB; MONOCLONAL ANTIBODY; NILOTINIB; OFATUMUMAB; PANITUMUMAB; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; SORAFENIB; SORAFENIB C 11; SUNITINIB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VEMURAFANIB; VEMURAFENIB; ANTIBODY CONJUGATE; DIAGNOSTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; RADIOISOTOPE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TARGETING; EOSINOPHILIC LEUKEMIA; GASTROINTESTINAL STROMAL TUMOR; GOOD MANUFACTURING PRACTICE; HEAD AND NECK CANCER; HODGKIN DISEASE; HYPEREOSINOPHILIC SYNDROME; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; PANCREAS CANCER; POSITRON; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; THYROID CANCER; ANIMAL; DRUG ANTAGONISM; DRUG SCREENING; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASM; SCINTISCANNING;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOCONJUGATES; MOLECULAR TARGETED THERAPY; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RADIOISOTOPES;

EID: 84863582789     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0316-4     Document Type: Review

References (54)

1. Walsh G. Biopharmaceutical benchmarks. Nat Biotechnol. 2010;28:917-24.
2. Mano M. The burden of scientific progress: growing inequalities in the delivery of cancer care. Acta Oncol. 2006;45:84-6.
3. Van Dongen GAMS, Visser GWM, Lub-de Hooge MN, De Vries EG, Perk LR. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist. 2007;12:1379-89.
4. Van Dongen GAMS, Vosjan MJWD. Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother Radiopharm. 2010;25:375-85.
5. Tolmachev V, Stone-Elander S, Orlova A. Radiolabelled receptortyrosinekinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol. 2010;11:992-1000.
6. De Vries EGE, Oude Munnink TH, Van Vugt MATM, Nagengast WB. Towards molecular imaging-driven drug development in oncology. Cancer Discovery. 2011. doi:10.1158/2159-8274. CD-11-0051.
7. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68:9280-90.
8. Tijink BM, Buter J, De Bree R, Giaccone G, Lang MS, Staab A, et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006;12:6064-72.
9. Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010;28:3965-72.
10. Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:3076-83.
11. 131I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging. 2009;36:1235-44.
12. 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271-81.
13. Nayak TK, Brechbiel MW. Radioimmunoimaging with longerlived positron-emitting radionuclides: potentials and challenges. Bioconjug Chem. 2009;20:825-41.
14. Tolmachev V, Stone-Elander S. Radiolabelled proteins for positron emission tomography: pros and cons of labelling methods. Biochim Biophys Acta. 2010;1800:487-510.
15. Holland JP, Williamson MJ, Lewis JS. Unconventional nuclides for radiopharmaceuticals. Mol Imaging. 2010;9:1-20.
16. Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol. 2009;36:729-39.
17. 89Zr-labeled anti-B-cell antibodies by small animal PET/CT. Appl Radiat Isot. 2011;69:852-7.
18. Perk LR, Vosjan MJWD, Visser GWM, Budde M, Jurek P, Kiefer GE, et al. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging. 2009;37:250-9.
19. Vosjan MJWD, Perk LR, Visser GWM, Budde M, Jurek P, Kiefer GE, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010;5:739-43.
20. 89Zr-labeled monoclonal antibodies for ImmunoPET. Nucl Med Biol. 2010;37:289-97.
21. Borjesson PKE, Jauw YWS, Boellaard R, De Bree R, Comans EFI, Roos JC, et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res. 2006;12:2133-40.
22. 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging. 2008;35:1857-67.
23. 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother Radiopharm. 2004;19:155-63.
24. 124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8:304-10.
25. 89Zr-labeled cG250-F (ab″) 2 in head and neck tumors. J Nucl Med. 2010;51:1076-83.
26. Heskamp S, Van Laarhoven HW, Molkenboer-Kuenen JD, Franssen GM, Versleijen-Jonkers YM, Oyen WJ, et al. ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J Nucl Med. 2010;51:1565-72.
27. 89Zr-DFO-J591 for ImmunoPETof prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010;51:1293-300.
28. 89Zr-7E11 Immuno-PET. J Nucl Med. 2011;52:1-8.
29. 89Zr-Df-TRC105. Eur J Nucl Med Mol Imaging. 2011. doi:10.1007/s00259-011-1930-x.
30. 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med. 2005;46:1898-906.
31. 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med. 2009;50:123-31.
32. 90Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging. 2006;33:1337-45.
33. Muylle K, Azerad MA, Perk LR, Meuleman N, Delrieu V, Ghanem G, et al. Immuno-PET/CT imaging with Zr-89-rituximab as a prelude for radioimmunotherpy with Y-90-rituximab in patients with relapsed CD20+ B cell non-Hodkin's lymphoma. Ann Oncol. 2008;19:179-80.
34. Nagengast WB, De Vries EG, Hospers GA, Mulder NH, De Jong JR, Hollema H, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med. 2007;48:1313-9.
35. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med. 2010;51:761-7.
36. 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med. 2009;50:974-81.
37. 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586-92.
38. 89Zr-DFO-trastuzumab. PLoS One. 2010;5:e8859.
39. Glekas AP, Pillarsetty NK, Punzalan B, Khan N, Smith-Jones P, Larson SM. In vivo imaging of Bcr-Abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib. J Nucl Med. 2011;52:1301-7.
40. Kil K-E, Ding Y-S, Lin K-S, Alexoff D, Kim SW, Shea C, et al. Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). Nucl Med Biol. 2007;34:153-63.
41. 11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor kinase. Bioorg Med Chem Lett. 2006;16:4102-6.
42. 11C] gefitinib for imaging epidermal growth factor receptor tyrosine kinase with positron emission tomography. J Lab Compd Radiopharm. 2006;49:883-8.
43. 11C]Iressa: radiosynthesis, in vitro uptake, and in vivo imaging of intact fibrosarcoma. Mol Imaging Biol. 2010;12:181-91.
44. 18F]-Iressa and related molecular probes. J Label Compd Radiopharm. 2005;48:829-43.
45. 18F]-gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging. 2008;35:1089-99.
46. 18F] SU11248, a new potential PET tracer for imaging cancer tyrosine kinase. Bioorg Med Chem Lett. 2005;15:4380-3.
47. 11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res. 2009;69:873-8.
48. 18F-lapatinib: a potential tracer for positron emission tomography imaging of Erb1/Erb2 tyrosine kinase activity. J Label Compd Radiopharm. 2011;54:633-6.
49. 11C]Sorafenib: radiosynthesis and preliminary PET study of brain uptake in P-gp/Bcrp knockout mice. Bioorg Med Chem Lett. 2011;21:2220-3.
50. Verel I, Visser GWM, Van Dongen GAMS. The promise of immuno-PET in radioimmunotherapy. J Nucl Med. 2005;46 Suppl 1:164S-71.
51. Olafsen T, Wu AM. Antibody vectors for imaging. Semin Nucl Med. 2010;40:167-81.
52. McKabe K, Wu AM. Positive progress in immunoPET-not just a coincidence. Cancer Biother Radiopharm. 2010;25:253-61.
53. 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med. 2009;50:1828-36.
54. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-32.